Inhibikase Therapeutics, Inc. financial data

Symbol
IKT on Nasdaq
Location
3350 Riverwood Parkway Se, Suite 1900, Atlanta, GA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.3K % +458%
Debt-to-equity 8.33 % -88.7%
Return On Equity -57.2 % +83.7%
Return On Assets -52.8 % +73.9%
Operating Margin -2.01B % -32475675%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75.2M shares +11.9%
Common Stock, Shares, Outstanding 74.8M shares +902%
Entity Public Float 7.7M USD -59.7%
Common Stock, Value, Issued 74.8K USD +902%
Weighted Average Number of Shares Outstanding, Basic 90.1M shares +914%
Weighted Average Number of Shares Outstanding, Diluted 90.1M shares +914%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 30.6M USD +135%
Costs and Expenses 51.1M USD +155%
Operating Income (Loss) -51.1M USD -155%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -47.7M USD -144%
Earnings Per Share, Basic 0 USD/shares +80%
Earnings Per Share, Diluted 0 USD/shares +80%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 56.5M USD +514%
Marketable Securities, Current 39.1M USD +1576%
Assets, Current 78.5M USD +1774%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 57.9K USD
Assets 79.6M USD +1719%
Accounts Payable, Current 621K USD -75.5%
Accrued Liabilities, Current 3.66M USD +69.2%
Liabilities, Current 6.7M USD +36.5%
Operating Lease, Liability, Noncurrent 25.6K USD -82.9%
Liabilities 6.7M USD +36.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.19K USD -339%
Retained Earnings (Accumulated Deficit) -130M USD -57.9%
Stockholders' Equity Attributable to Parent 72.9M USD
Liabilities and Equity 79.6M USD +1719%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.1M USD -6.12%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 21.1M USD
Common Stock, Shares Authorized 500M shares +400%
Common Stock, Shares, Issued 74.8M shares +902%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 38.3M USD +4090%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 23.2M USD +23.8%
Deferred Tax Assets, Gross 23.2M USD +23.8%
Operating Lease, Liability 37.9K USD -78.7%
Depreciation 67.1K USD +155%
Payments to Acquire Property, Plant, and Equipment 13.4K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.78M USD -25.7%
Lessee, Operating Lease, Liability, to be Paid 38.3K USD -79.9%
Property, Plant and Equipment, Gross 117K USD +12.9%
Operating Lease, Liability, Current 152K USD +2.88%
Lessee, Operating Lease, Liability, to be Paid, Year Two 115K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 378 USD -97%
Deferred Tax Assets, Operating Loss Carryforwards 12.3M USD +34.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 18.7M USD +5172%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%